UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Disease-modifying strategies for Parkinson's disease

Movement disorders, 2015-09, Vol.30 (11), p.1442-1450

2015

Volltextzugriff (PDF)

NMDA receptors in clinical neurology: excitatory times ahead

Lancet neurology, 2008-08, Vol.7 (8), p.742-755

2008

Volltextzugriff (PDF)

LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?

Frontiers in neuroscience, 2020-06, Vol.14, p.577-577

2020

Volltextzugriff (PDF)

Disease-associated mutations in C-terminus of HSP70 interacting protein (CHIP) impair its ability to negatively regulate mitophagy

Neurobiology of disease, 2024-10, Vol.200, p.106625, Article 106625

2024

Volltextzugriff (PDF)

High frequency electrical stimulation reduces α-synuclein levels and α-synuclein-mediated autophagy dysfunction

Scientific reports, 2024-07, Vol.14 (1), p.16091-17, Article 16091

2024

Volltextzugriff (PDF)

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein

Acta neuropathologica communications, 2020-02, Vol.8 (1), p.17-16, Article 17

2020

Volltextzugriff (PDF)

Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

Movement disorders, 2013-02, Vol.28 (2), p.131-144

2013

Volltextzugriff (PDF)

Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5)

PloS one, 2011-02, Vol.6 (2), p.e14695

2011

Volltextzugriff (PDF)

Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease

Nature communications, 2023-04, Vol.14 (1), p.2150-2150, Article 2150

2023

Volltextzugriff (PDF)

C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside

Current neuropharmacology, 2021-01, Vol.19 (7), p.1038-1068

2021

Volltextzugriff (PDF)

Reduction of alpha-synuclein oligomers in preclinical models of Parkinson’s disease by electrical stimulation in vitro and deep brain stimulation in vivo

Brain stimulation, 2024-03, Vol.17 (2), p.166-175

2024

Volltextzugriff (PDF)

Regulation of Parkin-dependent mitophagy by Bcl-2-associated athanogene (BAG) family members

Neural regeneration research, 2021-04, Vol.16 (4), p.684-685

2021

Volltextzugriff (PDF)

Schizophrenia susceptibility pathway neuregulin 1–ErbB4 suppresses Src upregulation of NMDA receptors

Nature medicine, 2011-04, Vol.17 (4), p.470-478

2011

Volltextzugriff (PDF)

Introduction: The Earliest Phase of Parkinson’s Disease: Possibilities for Detection and Intervention

Journal of Parkinson's disease, 2024-10, Vol.14 (s2), p.S253-S255

2024

Volltextzugriff (PDF)

Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis

Journal of visualized experiments, 2021-02 (168)

2021

Volltextzugriff (PDF)

Genetic Testing in Clinical Movement Disorders: A Case-Based Review

Seminars in neurology, 2023-02, Vol.43 (1), p.147-155

2023

Volltextzugriff (PDF)

Cavitation Feedback Control of Focused Ultrasound Blood-Brain Barrier Opening for Drug Delivery in Patients with Parkinson's Disease

Pharmaceutics, 2022-11, Vol.14 (12), p.2607

2022

Volltextzugriff (PDF)

Current Progress in Magnetic Resonance-Guided Focused Ultrasound to Facilitate Drug Delivery across the Blood-Brain Barrier

Pharmaceutics, 2024-05, Vol.16 (6), p.719

2024

Volltextzugriff (PDF)

Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans

Molecular neurodegeneration, 2021-11, Vol.16 (1), p.77-77, Article 77

2021

Volltextzugriff (PDF)

Biomarkers for cognitive dysfunction in Parkinson's disease

Parkinsonism & related disorders, 2018-01, Vol.46, p.S19-S23

Kalia, Lorraine V.

2018

Volltextzugriff (PDF)

If Art Were a Drug: Implications for Parkinson’s Disease

Journal of Parkinson's disease, 2024-01, Vol.14 (s1), p.S159-S172

2024

Volltextzugriff (PDF)

Neto1 is a novel CUB-domain NMDA receptor-interacting protein required for synaptic plasticity and learning

PLoS biology, 2009-02, Vol.7 (2), p.e41-e1000041

2009

Volltextzugriff (PDF)

Animal models of α-synucleinopathy for Parkinson disease drug development

Nature reviews. Neuroscience, 2017-09, Vol.18 (9), p.515-529

2017

Volltextzugriff (PDF)

First trials test targeting of α-synuclein for Parkinson disease

Nature reviews. Neurology, 2022-12, Vol.18 (12), p.703-704

Kalia, Lorraine V

2022

Volltextzugriff (PDF)

Evolving basic, pathological and clinical concepts in PD

Nature reviews. Neurology, 2016-02, Vol.12 (2), p.65-66

2016

Volltextzugriff (PDF)

1 – 25 von 153

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(150)
Mit Volltextzugriff
(132)

Publikationsform

Artikel
(149)
Berichte
(3)
Reviews
(1)

Sprache

Englisch
(153)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Disease-modifying strategies for Parkinson's disease

NMDA receptors in clinical neurology: excitatory times ahead

LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?

Disease-associated mutations in C-terminus of HSP70 interacting protein (CHIP) impair its ability to negatively regulate mitophagy

High frequency electrical stimulation reduces α-synuclein levels and α-synuclein-mediated autophagy dysfunction

Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein

Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5)

Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease

C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside

Reduction of alpha-synuclein oligomers in preclinical models of Parkinson’s disease by electrical stimulation in vitro and deep brain stimulation in vivo

Regulation of Parkin-dependent mitophagy by Bcl-2-associated athanogene (BAG) family members

Schizophrenia susceptibility pathway neuregulin 1–ErbB4 suppresses Src upregulation of NMDA receptors

Introduction: The Earliest Phase of Parkinson’s Disease: Possibilities for Detection and Intervention

Semi-Quantitative Determination of Dopaminergic Neuron Density in the Substantia Nigra of Rodent Models using Automated Image Analysis

Genetic Testing in Clinical Movement Disorders: A Case-Based Review

Cavitation Feedback Control of Focused Ultrasound Blood-Brain Barrier Opening for Drug Delivery in Patients with Parkinson's Disease

Current Progress in Magnetic Resonance-Guided Focused Ultrasound to Facilitate Drug Delivery across the Blood-Brain Barrier

Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans

Biomarkers for cognitive dysfunction in Parkinson's disease

If Art Were a Drug: Implications for Parkinson’s Disease

Neto1 is a novel CUB-domain NMDA receptor-interacting protein required for synaptic plasticity and learning

Animal models of α-synucleinopathy for Parkinson disease drug development

First trials test targeting of α-synuclein for Parkinson disease

Evolving basic, pathological and clinical concepts in PD

Suchergebnisse filtern